Literature DB >> 23665820

Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

J Tanaka1, H Kanamori, S Nishiwaki, K Ohashi, S Taniguchi, T Eto, H Nakamae, K Minagawa, K Miyamura, H Sakamaki, Y Morishima, K Kato, R Suzuki, N Nishimoto, K Oba, N Masauzi.   

Abstract

In this study, outcomes for 575 adult ALL patients aged ≥45 years who underwent first allo-SCT in CR were analyzed according to the type of conditioning regimen (myeloablative conditioning (MAC) for 369 patients vs reduced-intensity conditioning (RIC) for 206 patients). Patients in the RIC group were older (median age, 58 vs 51 years, P<0.0001). There were no statistically significant differences in 3-year OS, disease-free survival (DFS) and non-relapse mortality (NRM): 51% vs 53%, 47% vs 39% and 38% vs 36%, respectively. Multivariate analysis showed that CR2 and HLA mismatching were associated with poor OS (P=0.002 and P=0.019, respectively). HLA mismatching was associated with lower rate of relapse (P=0.016), but was associated with higher rate of NRM (P=0.001). RIC was associated with good OS and DFS in patients who received HLA-mismatch transplantation and were aged ≥55 years compared with MAC by multivariate analysis for each event with interaction (hazard ratio (HR) and 95% confidence interval 0.35 and 0.15-0.81, P=0.014 for OS and 0.36 and 0.16-0.81, P=0.013 for DFS). Therefore, patients ≥55 years of age with HLA-mismatch transplantation should be candidates for RIC rather than MAC.

Entities:  

Mesh:

Year:  2013        PMID: 23665820     DOI: 10.1038/bmt.2013.68

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Authors:  Gheath Alatrash; Kelly M Kidwell; Peter F Thall; Antonio Di Stasi; Julianne Chen; Madhushree Zope; Alyssa K Crain; Richard E Champlin; Uday Popat; Elizabeth J Shpall; Roy B Jones; Borje S Andersson
Journal:  Bone Marrow Transplant       Date:  2018-12-10       Impact factor: 5.483

2.  Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.

Authors:  Zinaida Peric; Myriam Labopin; Christophe Peczynski; Emmanuelle Polge; Jan Cornelissen; Ben Carpenter; Mike Potter; Ram Malladi; Jenny Byrne; Harry Schouten; Nathalie Fegueux; Gerard Socié; Montserrat Rovira; Jurgen Kuball; Maria Gilleece; Sebastian Giebel; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-05-02       Impact factor: 5.483

3.  Analysis of outcomes following autologous stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia during first complete remission.

Authors:  Harumi Kato; Takakazu Kawase; Shinichi Kako; Shuichi Mizuta; Mineo Kurokawa; Takehiko Mori; Kazuteru Ohashi; Koji Iwato; Koichi Miyamura; Michihiro Hidaka; Hisashi Sakamaki; Ritsuro Suzuki; Yasuo Morishima; Junji Tanaka
Journal:  Haematologica       Date:  2014-07-11       Impact factor: 9.941

4.  Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.

Authors:  Anne Banet; Ali Bazarbachi; Myriam Labopin; Nicolas Stocker; Rémy Duléry; Florent Malard; Zoé Van de Wyngaert; Alexis Genthon; Mara Memoli; Ollivier Legrand; Agnes Bonnin; Tounes Ledraa; Ramdane Belhocine; Simona Sestili; Jean El-Cheikh; Mohamad Mohty; Eolia Brissot
Journal:  Bone Marrow Transplant       Date:  2022-10-12       Impact factor: 5.174

5.  Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.

Authors:  Matthew D Seftel; Donna Neuberg; Mei-Jie Zhang; Hai-Lin Wang; Karen Kuhn Ballen; Julie Bergeron; Stephen Couban; César O Freytes; Mehdi Hamadani; Mohamed A Kharfan-Dabaja; Hillard M Lazarus; Taiga Nishihori; Kristjan Paulson; Wael Saber; Stephen E Sallan; Robert Soiffer; Martin S Tallman; Ann E Woolfrey; Daniel J DeAngelo; Daniel J Weisdorf
Journal:  Am J Hematol       Date:  2016-03       Impact factor: 10.047

Review 6.  Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

Authors:  S Fadilah Abdul Wahid; Nor-Azimah Ismail; Mohd-Razif Mohd-Idris; Fariza Wan Jamaluddin; NorRafeah Tumian; Ernie Yap Sze-Wei; Norasiah Muhammad; Ming Lai Nai
Journal:  Stem Cells Dev       Date:  2014-09-17       Impact factor: 3.272

7.  Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.

Authors:  Daniel Fürst; Dietger Niederwieser; Donald Bunjes; Eva M Wagner; Martin Gramatzki; Gerald Wulf; Carlheinz R Müller; Christine Neuchel; Chrysanthi Tsamadou; Hubert Schrezenmeier; Joannis Mytilineos
Journal:  Haematologica       Date:  2017-01-05       Impact factor: 9.941

Review 8.  A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.

Authors:  Erden Atilla; Pınar Ataca Atilla; Taner Demirer
Journal:  Balkan Med J       Date:  2017-01-05       Impact factor: 2.021

Review 9.  Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning.

Authors:  Masahiro Imamura; Akio Shigematsu
Journal:  Exp Hematol Oncol       Date:  2015-07-16

10.  Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.

Authors:  Gabrielle Roth-Guepin; Jonathan Canaani; Annalisa Ruggeri; Myriam Labopin; Juergen Finke; Jan J Cornelissen; Jeremy Delage; Gernot Stuhler; Monserrat Rovira; Mike Potter; Michael Stadler; Hendrik Veelken; Jean Yves Cahn; Matthew Collin; Yves Beguin; Sebastian Giebel; Arnon Nagler; Mohamad Mohty
Journal:  Oncotarget       Date:  2017-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.